Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.75
€0.00(0.00%)
At close: 4:00 PM EDT
€2.75
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.11 - €3.89
Previous CloseN/A
Volume3.25K
Average Volume (3M)4.01K
Market Cap
€55.93M
Enterprise Value€116.09M
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Jan 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding21,847,494
10 Day Avg. Volume3,424
30 Day Avg. Volume4,009
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€55.10M
Bulls Say, Bears Say
Bulls Say
Industrial Biotechnology PlatformThe company operates in industrial biotechnology, applying microbial diversity and enzyme expertise across food, feed, detergents, and manufacturing. This platform spans multiple end markets and provides a foundation for developing specialized solutions through research and partner collaborations.
Improving Gross MarginThe improvement in gross margin indicates better economics at the product level than in the prior annual periods. If sustained, stronger gross profitability could support operating leverage and improve the company’s ability to convert revenue growth into lower losses over time.
No TTM Debt ReportedReported TTM debt of zero reduces direct interest and refinancing pressure compared with a heavily debt-funded structure. This provides some balance-sheet support, although the benefit is tempered by the company’s negative equity and historically volatile funding profile.
Bears Say
Persistent UnprofitabilityThe company remains deeply loss-making despite improved gross margin, showing that gross-profit gains have not yet covered operating costs. Persistent operating and net losses weaken internal funding capacity and make a durable path to self-sustaining earnings dependent on further performance improvement.
Ongoing Cash BurnNegative operating and free cash flow show that the business is consuming cash rather than funding operations internally. Continued burn reduces financial flexibility, limits reinvestment capacity, and increases dependence on external funding to sustain development and commercial activities.
Negative Shareholders’ EquityNegative shareholders’ equity is a material balance-sheet weakness because accumulated losses exceed the company’s equity base. This leaves less capacity to absorb further losses and raises funding and solvency concerns, particularly given the reported volatility in its historical capital structure.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €2.11 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €55.93M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Jan 14, 2027 which is in 77 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on Aug 27, 2026. The company reported -€0.163 earnings per share for the quarter.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.163 in its last earnings report. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
590.52%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.